Market Place
Sourcing Support
Ritedose Partners With Verona To Deliver First-In-Class COPD Drug Ohtuvayre
17 Sep 2024 //
PR NEWSWIRE
Verona Pharma To Present Ph3 COPD Study Analyses At ERS Congress
05 Sep 2024 //
GLOBENEWSWIRE
Verona Pharma Reports Q2 2024 Results And Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
Verona Pharma To Report Q2 2024 Results And Give Corporate Update
24 Jul 2024 //
GLOBENEWSWIRE
Verona`s price for COPD drug far exceeds ICER`s valuation
16 Jul 2024 //
FIERCE PHARMA
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
26 Jun 2024 //
GLOBENEWSWIRE
Verona`s Ensifentrine Called `Paradigm Shift` For COPD By GlobalData
30 May 2024 //
FIERCE PHARMA
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
10 May 2024 //
PRESS RELEASE
Verona Pharma Q1 2024 Financials And Corporate Update
09 May 2024 //
GLOBENEWSWIRE
Verona Pharma to Host Update on Commercialization Preparation for Ensifentrine
06 Oct 2023 //
GLOBENEWSWIRE
Verona Pharma Announces the US FDA has Accepted the NDA Filing for Ensifentrine
11 Sep 2023 //
GLOBENEWSWIRE
Verona Pharma submits FDA New Drug Application for COPD treatment
27 Jun 2023 //
PHARMAFILE
Second PIII win for Verona`s ensifentrine in COPD sets up FDA filing
21 Dec 2022 //
ENDPTS
Verona Pharma Announces Ensifentrine Meets Primary & Key Secondary Endpoints
20 Dec 2022 //
GLOBENEWSWIRE
Verona Announces Analyses Demonstrating Ensifentrine ReducedExacerbation Rates
13 Oct 2022 //
GLOBENEWSWIRE
Nuance Pharma Announces Clearance of IND Application for Ensifentrine Trials
18 Aug 2022 //
PRNEWSWIRE
Verona Pharma Reports Results from Phase 3 ENHANCE-2 Trial Ensifentrine
12 Aug 2022 //
TRIALSITES
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial
08 Aug 2022 //
GLOBENEWSWIRE
Verona Pharma Completes Enrollment in PIII ENHANCE-1 Trial of Ensifentrine
09 Jun 2022 //
GLOBENEWSWIRE
UK Pharma invests $219M to scale up respiratory drug in China, Taiwan, HK, Macau
24 Jun 2021 //
BIOSPECTRUMASIA
Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration
10 Jun 2021 //
PRNEWSWIRE
Verona Pharma launches late-stage COPD trial programme
23 Sep 2020 //
PHARMATIMES
Verona Pharma Initiates PhIII Clinical Trials with Nebulized Ensifentrine
22 Sep 2020 //
GLOBENEWSWIRE
Repurposing a COPD drug for Covid-19 with Verona Pharma
21 Sep 2020 //
PHARMACEUTICAL TECHNOLOGY
Verona Pharma Announces Publication of Phase 2b COPD Symptom Data
16 Sep 2020 //
PRESS RELEASE
Verona to test copd hopeful Ensifentrine in covid-19 patients
13 Sep 2020 //
PHARMA PHORUM
Inhaled ensifentrine will be assessed in hospitalised patients
07 Sep 2020 //
PHARMATIMES
Priority review for Imfinzi`s less-frequent dosing regimen
19 Aug 2020 //
PHARMATIMES
Verona Pharma Announces FDA Response to End-of-Phase 2 for Ensifentrine
14 May 2020 //
GLOBENEWSWIRE
Ensifentrine improves lung function in COPD patients
31 Mar 2020 //
PHARMA TIMES
Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI
31 Mar 2020 //
VERONAPHARMA
Verona unveils Phase II COPD results
14 Feb 2020 //
PHARMA TIMES
Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study
13 Jan 2020 //
PRESS RELEASE
Verona Pharma (VRNA) Jumps 45% On Looming Trial Data
28 Dec 2019 //
NASDAQ
Verona Pharma Completes Enrollment in Phase 2b Trial with Nebulized Ensifentrine
17 Oct 2019 //
BIOSPACE
Verona Pharma share positive ensifentrine results in COPD
06 Aug 2019 //
PHARMA TIMES
Another EU patent for Verona in COPD drug
10 Apr 2019 //
PHARMA TIMES
Verona Pharma Receives WHO Approval for ensifentrine as INN for RPL554
09 Jan 2019 //
GLOBENEWSWIRE
Verona Pharma Completes Enrollment in Phase 2 Clinical Trial
30 Nov 2018 //
DRUG DEV NEWS
Verona jumps as midphase cystic fibrosis data dial up hopes
02 Mar 2018 //
FIERCE BIOTECH
Verona’s RPL554 improves lung function in CF trial
02 Mar 2018 //
PHARMA TIMES
Verona Pharma begins dosing RPL554 in Phase IIb COPD trial
26 Jul 2017 //
PHARMA TIMES
